Bayer CropScience Ltd
Bayer CropScience Q2 FY19 earnings call: Revenue & Margins
Q2 FY19 investor presentation: what the company reported on revenue, margins and projects.
Based on Bayer CropScience Ltd's Q2 FY19 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 2018 Key Data (Page 5): - Sales: €9,905 million - Year-on-year change (currency- and portfolio-adjusted): +4.1% - Crop Science segment sales: €3,733 million, -9.5% - EBITDA: 304 million, -13.5% - First Nine Months of 2018 Key Data (Page 6): - Sales: €28,524 million - Year-on-year change (currency- and portfolio-adjusted): +3.6% - Crop Science segment sales: €9,605 million, +3.2% - No explicit revenue or volume figures stated for the quarter beyond above sales and EBITDA metrics. Quarterly EBITDA: INR 1,297 million, up +3.0% YoY (Page 5) - Quarterly Operating Margin (EBITDA margin): Not explicitly stated for the quarter; however, FY18 EBITDA margin reported at 14.9% (Page 15) - Profit After Tax (PAT): Not explicitly stated for the quarter; Profit Before Tax shows a +13% increase YoY (Page 19) - Other financial figures: - Revenue for the year ended March 31, 2018, BCSL: INR 27,490 million; MIL: INR 6,721 million (Page 15) - EBITDA margin BCSL: 14.9%, MIL: 25.2% (Page 15) - Margin Outlook: The presentation does not explicitly provide a defined margin outlook but mentions discipline in business focus and confident leadership in price realization to mitigate cost increases (Page 27).
From Bayer CropScience Ltd's Q2 FY19 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 2018 Key Data (Page 5):
- Sales: €9,905 million
- Year-on-year change (currency- and portfolio-adjusted): +4.1%
- Crop Science segment sales: €3,733 million, -9.5%
- EBITDA: 304 million, -13.5%
- First Nine Months of 2018 Key Data (Page 6):
- Sales: €28,524 million
- Year-on-year change (currency- and portfolio-adjusted): +3.6%
- Crop Science segment sales: €9,605 million, +3.2%
- No explicit revenue or volume figures stated for the quarter beyond above sales and EBITDA metrics.
- Outlook (Pages 26, 27, 28):
- Business expected to return to growth in remainder of FY 2018-19
- Launch of 2 products till Q4 FY 2018-19 and 5 more thereafter expected to capture market value
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bayer CropScience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bayer CropScience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Bayer CropScience Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bayer CropScience Ltd's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Aries Agro Ltd (Q2 FY19)
The company achieved a conversion rate of approximately 75-80% from these orders. Key concall takeaways from Aries Agro Ltd's Q2 FY19 earnings call — and how…
Frequently Asked Questions
What were Bayer CropScience Ltd Q2 FY19 results?
Q3 2018 Key Data (Page 5): - Sales: €9,905 million - Year-on-year change (currency- and portfolio-adjusted): +4.1% - Crop Science segment sales: €3,733 million, -9.5% - EBITDA: 304 million, -13.5% - First Nine Months of 2018 Key Data (Page 6): - Sales: €28,524 million - Year-on-year change (currency- and portfolio-adjusted): +3.6% - Crop Science segment sales: €9,605 million, +3.2% - No explicit revenue or volume figures stated for the quarter beyond above sales and EBITDA metrics. Quarterly EBITDA: INR 1,297 million, up +3.0% YoY (Page 5) - Quarterly Operating Margin (EBITDA margin): Not explicitly stated for the quarter; however, FY18 EBITDA margin reported at 14.9% (Page 15) - Profit After Tax (PAT): Not explicitly stated for the quarter; Profit Before Tax shows a +13% increase YoY (Page 19) - Other financial figures: - Revenue for the year ended March 31, 2018, BCSL: INR 27,490 million; MIL: INR 6,721 million (Page 15) - EBITDA margin BCSL: 14.9%, MIL: 25.2% (Page 15) - Margin Outlook: The presentation does not explicitly provide a defined margin outlook but mentions discipline in business focus and confident leadership in price realization to mitigate cost increases (Page 27).
What is Bayer CropScience Ltd share price analysis?
Bayer CropScience Ltd currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹16,986 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bayer CropScience Ltd planning capital expenditure?
The investor presentation does not explicitly mention any specific capex amounts, capacity expansions, new plants, or projects with detailed statuses or timelines.
Keep Bayer CropScience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.